Chemical library

Inkemia, through its new platform, is able to get new Drug Discovery compounds in a more efficient and flexible way than other companies.

Such platform is capable of designing, synthetizing and evaluating candidate molecules to interact with pharmacological targets.

We have the work teams, the infrastructure, know-how and a wide experience in:

-        Design and chemistry synthesis.

-        Medicinal chemistry.

-        High Throughput Experimentation.

-        High Throughput Analysis.

-        Structural elucidation and

-        Intellectual Property search.

More over, our team has a lot of experience in:

-        Organic synthesis, biotechnology and biocatalysis processes through the use of proprietary enzymes or with live microorganisms.

-        Computational chemistry tools for “in silico” design of candidates.

-        Specific know-how on scale up process for the afterwards production of industrial products.

Among our activities you can choose between: the design and modification of scaffolds, “de novo” structure design, the design of routes of scaffolds and libraries, the synthesis of scaffolds and building blocks, transformation of multi step processes to one-pot reactions, highly chemical, region and stereo selective processes, low cost developments, exclusive processes...and many others.

As a summary, Inkemia offer you:

-        Flexibility: up to complementary 4 ways of synthesis of compounds.

-        Added value: we not only provide you the desired compounds but as well the whole synthesis pathway for a further pilot or industrial scale up.

-        We can produce any type of native, recombinant or mutant enzyme.

-        Wide experience and background in analysis and synthesis.

We also have a wide collection of molecules and hits in cancer and other diseases (viral, inflammation, coagulation, etc.) available for its licensing o Codevelopment Agreements.

1)              Chemical library of new nucleoside analogues for tests of anticancer activity: through the HTB platform, IUCT has a powerful technological tool to design libraries of hundreds of new nucleoside analogues through the synergy of coupling biotechnological and organic synthesis tools.

There are currently about 500 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

 Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new anticancer drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Delivery and scale-up: it is possible to re-synthesize or to scale the products up to 1-2 g.

We also have hits available for its licensing or for Codevelopment Agreements in several cancer indications: lung, breast, colon, liver, prostate, kidney, pancreas, lymphoma, leukaemia and glioblastoma.

2)              Chemical library of new nucleoside analogues for tests of antiviral activity: through the HTB platform, IUCT owns a powerful technological tool to construct libraries of new nucleoside analogues through the synergy of coupling biotechnologic and organic synthesis tools

There are currently about 500 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new antiviral drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Delivery and scale-up: it is possible to re-synthesize or to scale the products up to 1-2 g.

3)          Chemical libraries of novel sulphonamides as antagonists of receptors involved in inflammatoryprocesses: the compounds have been designed as antagonists of Bradykinin B1 and B2 receptors that mediate pain and inflammation, involved in inflammatory processes like: respiratory diseases (asthma, rinitis), arthritis, pancreatitis, sepsis, etc.

There are currently about 200 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for most of the molecules in the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new anti-inflammatory drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Robust synthetic schemes: it is possible to re-synthesize or to scale-up the products according to the development stage.

4)              Chemical libraries of novel sulphonamides for anticoagulation tests: the compounds have been designed as inhibitors of several proteins involved in the coagulation process: Thrombine (Factor FIIa), Activated Factor X (FXa), Coagulation Factor VIIa, Trypsin, Coagulation Factor IX, etc.

There are currently about 200 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits or lead compounds in the R&D of new anticoagulant drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Robust synthetic schemes: it is possible to re-synthesize or to scale-up the products according to the development stage.

5)              Library of tropanic compounds: library of tropanic compounds with activity on the Central Nervous System (CNS). 

There are currently about 30 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Possibility of identifying hits orlead compounds in the R&D of new compounds in the aforementioned indications from derived compounds of a structure with activity in this field.

-        Very complex synthesis optimized.

We also have 3 hits that have shown an improvement in the motor activity in a flies’ model with Parkinson Disease, available for its licensing or Codevelopment Agreements. If you want more

Contact

  •   info@inkemia.com
  •  +34 93 579 34 32
  •  +34 93 570 57 45
  •  C\ Àlvarez de Castro, 63, 08100
    Mollet del Vallès (Barcelona)